U.S. Biotech Reports Major Survival Gain in Pancreatic Cancer as Hiroshima Plans 2028 Trial for MicroRNA Mesothelioma Drug

Overview

• Revolution Medicines announced Thursday that a company‑reported trial of its oral candidate, ダラクソンラシブ, nearly doubled overall survival versus standard chemotherapy in previously treated metastatic pancreatic cancer and said the results were published in a U.S. scientific journal.
• The company said the drug reduced the risk of death by about 60 percent in the trial and plans to seek regulatory approval with the U.S. Food and Drug Administration designating the program for expedited review.
• The trial tested the oral therapy in patients whose cancer had progressed after prior treatments, a population that typically faces very low survival, making large gains potentially meaningful if confirmed.
• Separately, Hiroshima University researchers announced plans to launch an international clinical trial around 2028 of a microRNA‑based therapy that aims to induce senescence in malignant pleural mesothelioma cells after early‑stage safety testing.
• Experts and regulators will now need to review the published data and confirm the findings in larger, independent trials; key next steps to watch are regulatory filings, peer review details, and results from confirmatory studies that will determine real‑world benefit and patient access.